-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11

Benzinga·10/28/2026 23:14:09
Listen to the news
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.